Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.60 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.60 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 7/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | NOS3 | P29474 | 1/20 | 0.54 |
| ▸ | NOS1 | P29475 | 1/20 | 0.54 |
| ▸ | NOS2 | P35228 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.53 |
| ▸ | NCF1 | P14598 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15467001 | 0.86 | HRH3 (0.87) | HRH3HIF1AEPAS1SMN1; SMN2NOS3 | |
| SCHEMBL22889633 | 0.84 | HRH3 (0.65) | HRH3HIF1AEPAS1SMN1; SMN2NPC1 | |
| SCHEMBL5095148 | 0.84 | HRH3 (0.65) | HRH3HIF1AEPAS1SMN1; SMN2NPC1 | |
| SCHEMBL5993766 | 0.83 | HRH3 (0.69) | HRH3SMN1; SMN2ALDH1A1NCF1 | |
| SCHEMBL15137345 | 0.82 | SIGMAR1 (0.57) | HRH3AOC3HTTMEN1KMT2A | |
| SCHEMBL13946389 | 0.82 | NCF1 (0.65) | HRH3HIF1AEPAS1SMN1; SMN2NPC1 | |
| SCHEMBL5008349 | 0.81 | ALDH1A1 (0.62) | HRH3SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL4998852 | 0.81 | HRH3 (0.64) | HRH3HIF1AEPAS1AOC3SMN1; SMN2 | |
| SCHEMBL60797 | 0.81 | HRH3 (0.71) | HRH3HIF1AEPAS1AOC3SMN1; SMN2 | |
| SCHEMBL113089 | 0.81 | NCF1 (0.74) | HRH3HIF1AEPAS1AOC3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744651-A2 | A PI3K-DELTA INHIBITOR FOR USE IN TREATMENT REGIMENS | iOnctura SA (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4727554-A1 | COMBINATIONS OF IOA-244, A PD-1 OR PD-L1 INHIBITOR AND A CHEMOTHERAPEUTIC AGENT TO TREAT CANCER | iOnctura SA (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-12605389-B2 | PI3K-δ inhibitor for use in treatment regimens | IONCTURA SA (CH) | 2026-04-21 | — | — | US | disclosed |
| EP-4676478-A1 | COMBINATION OF ROGINOLISIB AND BCL-2 INHIBITOR IN THE TREATMENT OF HAEMATOLOGICAL MALIGNANCY | iOnctura SA (CH) | 2026-01-14 | — | — | EP | disclosed |
| EP-4676454-A1 | COMBINATION OF ROGINOLISIB AND HDAC INHIBITOR IN THE TREATMENT OF HAEMATOLOGICAL MALIGNANCY | iOnctura SA (CH) | 2026-01-14 | — | — | EP | disclosed |
| CN-115836077-B | Oxazaspiro derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025073968-A1 | COMBINATION OF ROGINOLISIB WITH A MALT1-GLS INHIBITOR | IONCTURA SA (CH) | 2025-04-10 | — | — | WO | disclosed |
| EP-4313058-B1 | COMPOSITION COMPRISING ROGINOLISIB AND DOSAGE REGIME FOR TREATING CANCER OR AN INFLAMMATORY OR AUTOIMMUNE DISEASE | IONCTURA SA (CH) | 2025-03-05 | — | — | EP | disclosed |
| WO-2024256552-A1 | COMBINATIONS OF IOA-244, A PD-1 OR PD-L1 INHIBITOR AND A CHEMOTHERAPEUTIC AGENT TO TREAT CANCER | IONCTURA SA (CH) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024184266-A1 | COMBINATION OF ROGINOLISIB AND HDAC INHIBITOR IN THE TREATMENT OF HAEMATOLOGICAL MALIGNANCY | IONCTURA SA (CH) | 2024-09-12 | — | — | WO | disclosed |
| US-7691888-B2 | Thiazolyl-dihydro-indazole | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-7691888-B2 | Thiazolyl-dihydro-indazole | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-7691888-B2 | Thiazolyl-dihydro-indazole | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| EP-1799690-B1 | THIAZOLYL-DIHYDRO INDAZOLES | BOEHRINGER INGELHEIM INT (DE) | 2008-04-16 | — | — | EP | disclosed |
| EP-1799690-B1 | THIAZOLYL-DIHYDRO INDAZOLES | BOEHRINGER INGELHEIM INT (DE) | 2008-04-16 | — | — | EP | disclosed |
| EP-1857446-A1 | NOVEL HSP90 INHIBITOR | Nippon Kayaku Kabushiki Kaisha (JP) | 2007-11-21 | — | — | EP | disclosed |
| CN-101035795-A | Thiazolyl dihydroindazoles | BOEHRINGER INGELHEIM INT (DE) | 2007-09-12 | — | — | CN | disclosed |
| EP-1799690-A1 | THIAZOLYL-DIHYDRO INDAZOLES | Boehringer Ingelheim International GmbH (DE) | 2007-06-27 | — | — | EP | disclosed |
| US-20060100254-A1 | N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
| WO-2006040281-A1 | THIAZOLYL-DIHYDRO INDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100254-A1 | N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases | CDK1, MAPK1, NFATC1 | HRH3 1999/4885HIF1A 1500/4885EPAS1 926/4885 |
| US-12605389-B2 | PI3K-δ inhibitor for use in treatment regimens | PIK3CD, PIK3R5, PIK3R4 | HRH3 2867/4885HIF1A 3393/4885EPAS1 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.